entertainment -WSS

entertainment

author：leisure time 2025-08-04 05:22:32 - browse：942

Insitro CEO and founder Daphne Koller Neilson Barnard/Getty Images for The New York Times

SAN FRANCISCO — It took only a single, one-hour meeting in a Starbucks to convince venture capitalist Robert Nelsen that he was going to invest in the company being built by machine-learning whiz Daphne Koller. “She’s just an amazing force of nature,” said Nelsen, who invests for ARCH Venture Partners.

Koller’s company, Insitro, in a matter of months raised over $100 million from big-name investors including ARCH, Foresite Capital, Andreessen Horowitz, and the firm that manages Jeff Bezos’ personal VC investments. (Koller refers to Bezos by his first name.) Now, it’s time for the next step. On Tuesday, the giant drug maker Gilead Sciences said it would pay Insitro $15 million — and up to $1 billion more down the line if it meets certain goals — for help in developing drugs to treat a common liver disease. It is the South San Francisco-based company’s first deal with a drug maker, and offers a test of whether artificial intelligence can remake drug development.

The very nature of the financials emphasize the exciting but risky reality: The technology has great promise, but nothing is guaranteed.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Wildfire smoke exposes gaps in outdoor worker protections
Next article： Readout Newsletter: Bayer, Rapt Therapeutics, Sanofi shortage

entertainment

WSS

Medicare Advantage enrollment hits roughly 33.4 million

Trump demands the U.S. pay no more for drugs than other countries … again

Flagship Pioneering startup Sonata Therapeutics lays off 21

Tori Bowie and the unacceptable rates of Black maternal death

The high cost of giving birth even with insurance

Psychedelics group wrestles with new pharma identity

knowledge

entertainment

entertainment

Novavax promises a turnaround & Lilly roils the obesity market

Psychedelics group wrestles with new pharma identity

In age of alternative facts, a scholarly course on calling out crap

The cancer drug shortage isn’t new — and neither are the solutions

Guidelines to prevent youth baseball injuries need more muscle

Alkermes shareholders re

George Santos makes 1st court appearance after pleading not guilty to 13 counts

Medical leaders decry Supreme Court decision on affirmative action

Activists slam private health insurers over coverage restrictions

Medicare proposal to cover medical devices draws a mixed reaction

explore

State Dept. review finds Biden bears some blame for Afghanistan failures

Drug repurposing or repositioning? The language matters

Bipartisan group of lawmakers warns of a rising Chinese threat to U.S. biotech

The high cost of giving birth even with insurance

MD Anderson's Padmanee Sharma responds to research credit suit

Hepatitis C has a cure — but many Americans still lack access to it

focus

knowledge

entertainment

leisure time